HALO logo

Halozyme Therapeutics Inc. (HALO)

$96.50

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on HALO

Market cap

$11.00B

EPS

4

P/E ratio

32.2

Price to sales

7.53

Dividend yield

--

Beta

0.919809

Price on HALO

Previous close

$100.27

Today's open

$101.72

Day's range

$96.40 - $101.75

52 week range

$61.23 - $134

Profile about HALO

CEO

Helen I. Torley

Employees

423

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

114010000

Issue type

Common Stock

HALO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on HALO

HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?

Halozyme surges 43.1% in six months on strong ENHANZE-driven royalties and higher revenue guidance.

news source

Zacks Investment Research • 12 hours ago

news preview

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?

Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?

Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

news source

Zacks Investment Research • Nov 10, 2026

news preview

NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump

NVIDIA's controversy and AI market correction prompt investors to explore healthcare, consumer staples and selective semiconductor opportunities.

news source

Zacks Investment Research • Nov 10, 2026

news preview

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

Halozyme Therapeutics NASDAQ: HALO raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous drug launches.

news source

MarketBeat • Nov 6, 2026

news preview

HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.

news source

Zacks Investment Research • Nov 6, 2026

news preview

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication does not include patients with oropharyngeal squamous cell carcinoma that is HPV-associated.

news source

PRNewsWire • Nov 6, 2026

news preview

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026. "Based on our analysis of CMS's final rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.

news source

PRNewsWire • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Halozyme Therapeutics Inc.

Open an M1 investment account to buy and sell Halozyme Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in HALO on M1